These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38874905)

  • 1. Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
    Peng JY; Wang SY; Chen MQ; Liu CX; Zhao YT; Xu TS; Wu QL
    Blood Coagul Fibrinolysis; 2024 Jul; 35(5):271-278. PubMed ID: 38874905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
    He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
    Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
    Miyakawa Y; Imada K; Ichikawa S; Uchiyama H; Ueda Y; Yonezawa A; Fujitani S; Ogawa Y; Matsushita T; Asakura H; Nishio K; Suzuki K; Hashimoto Y; Murakami H; Tahara S; Tanaka T; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):366-377. PubMed ID: 36427162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
    Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
    Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
    Kühne L; Knöbl P; Eller K; Thaler J; Sperr WR; Gleixner K; Osterholt T; Kaufeld J; Menne J; Buxhofer-Ausch V; Mühlfeld A; Seelow E; Schreiber A; Todorova P; Cukoski S; Jabs WJ; Özcan F; Gäckler A; Schönfelder K; Seibert FS; Westhoff T; Schwenger V; Eichenauer DA; Völker LA; Brinkkoetter PT
    Blood; 2024 Oct; 144(14):1486-1495. PubMed ID: 38838300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP.
    Saito K; Sakai K; Kubo M; Azumi H; Hamamura A; Ochi S; Amagase H; Kunieda H; Ogawa Y; Yagi H; Matsumoto M
    Blood Adv; 2024 May; 8(9):2151-2159. PubMed ID: 38386976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
    Tse B; Buchholz M; Pavenski K
    Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod A; Veyradier A; Coppo P
    J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience.
    Taylor A; Keogh L; Dickens E; Dutt T; Grainger J; Gregory R; Mapplebeck C; Richards M; Stokley S; Salta S; Taylor T; Scully M
    Blood Adv; 2024 Sep; 8(17):4563-4567. PubMed ID: 38968147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.
    Pavenski K; Scully M; Coppo P; Cataland S; Knöbl P; Peyvandi F; Kremer Hovinga JA; de la Rubia J; Khan U; Marques AP; Gunawardena S
    Res Pract Thromb Haemost; 2024 Jul; 8(5):102512. PubMed ID: 39221451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura.
    Völker LA; Brinkkoetter PT; Cataland SR; Masias C
    J Thromb Haemost; 2023 Oct; 21(10):2718-2725. PubMed ID: 37562668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
    Coppo P; Joly BS;
    Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
    Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
    J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era.
    Prasannan N; Thomas M; Stubbs M; Westwood JP; de Groot R; Singh D; Scully M
    Blood; 2023 May; 141(18):2206-2213. PubMed ID: 36720103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.